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Abstract
Background—The prevalence of hepatitis C (HCV) and HIV among persons who inject drugs 
(PWID) and the ability of these diseases to spread through injection networks are well documented 
in urban areas. However, less is known about injection behaviors in rural areas.
Objectives—This study focuses on the association between the number of self-reported injection 
partners with the PWID’s self-reported HCV and HIV status. Injection networks provide paths for 
infection and information to flow, and are important to consider when developing prevention and 
intervention strategies.
Methods—Respondent driven sampling was used to conduct 315 interviews with PWID in rural 
Puerto Rico during 2015. Negative binomial regression was used to test for associations between 
the number of self-reported injection partners and self-reported HCV and HIV statuses. 
Multinomial logistic regression was used to test for associations with the participant’s self-
reported HCV and HIV statuses.
Results—Self-reported HCV status is significantly associated with injection risk network size. 
Injection partner networks of self-reported HCV− respondents are half what is reported by those 
with a positive or unknown status. Self-reported HIV statuses are not associated with different 
numbers of injection partners.
Conclusions—Smaller injection networks among those who self-reporta HCV− status suggests 
that those who believe their status to be negative may take protective action by reducing their 
injection network compared to those have a self-reported HCV+ or an unknown status. Although 
the cross-sectional design of the study makes it difficult verify, such behavior has implications for 
prevention programs attempting to prevent HCV transmission.
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The high prevalence of the hepatitis C virus (HCV) among people who inject drugs (PWID) 
has been well documented, with estimates ranging from 60% to 80% globally (Nelson et al., 
2011), 50% to 60% in the United States mainland (Lansky et al., 2014) and up to 89% in 
Puerto Rico (Reyes et al., 2006). HCV spreads through unsafe injection practices (Hagan et 
al., 2001), can be symptomless for many years (D. J. Smith, Combellick, Jordan, & Hagan, 
2015), and has been linked to social network characteristics of injectors (Brewer et al., 2006; 
Sacks-Davis et al., 2012). HCV testing and counseling has become a readily accepted aspect 
of interventions for PWID (CDC, 2013; WHO, n.d.). Such strategies assume that awareness 
of a HCV status will influence injection risk behavior in a positive manner, reducing the 
spread of the HCV virus (Aspinall et al., 2014; Cox et al., 2009). This assumption is based 
on proven HIV intervention strategies which contain strong elements of testing information, 
education, and counseling (MacArthur et al., 2014) to reduce risky behavior and further 
disease transmission.
Social networks among PWID provide paths for infections and information to spread across. 
In recent years studies have traced different viral genotypes of HCV across networks, 
demonstrating how the spread of specific types of HCV are associated with network 
characteristics (Pilon et al., 2011; Romano et al., 2010; Sacks-Davis et al., 2012). Here, 
clusters of related HCV genotypes have been found within groups of injection partners 
(Sacks-Davis et al., 2012) and also associated with disparate social networks of injection 
partners in Brazil (Romano et al., 2010) and Canada (Pilon et al., 2011). Other studies 
focused on the risk of HCV spread found that over 78% of injection partnerships (network 
connections) involved behavior that could transmit HCV (Brewer et al., 2006); even 
knowing someone else who injected increased a PWID’s odds of contracting HIV or HCV 
(Latkin et al., 2011). Overall, networks seem to matter, but it remains largely unknown how 
PWID injection risk network interactions may reflect local understandings and self-
perceptions of one’s HCV status.
There is a lack of clear evidence on whether individual PWID risk network behavior may 
reflect or respond to self-reported HCV status. Smith and colleagues (B. D. Smith et al., 
2013) found that PWID had higher odds of sharing injection materials when they shared the 
same self-reported HCV status and other studies have found a variety of behavioral changes 
associated with learning actual HCV status (Hahn, Evans, Davidson, Lum, & Page, 2010; 
Kwiatkowski, Fortuin Corsi, & Booth, 2002; Vidal-Trécan, Coste, Varescon-Pousson, 
Christoforov, & Boissonnas, 2000). In each of these studies the emphasis was on changes in 
risk network behavior that accompanied a transition from self-reported to known HCV 
status. However, these changes are not confined to learning about either a negative (Hagan et 
al., 2006) or positive HCV result (Bruneau et al., 2014; Spelman et al., 2015; Vidal-Trécan 
et al., 2000), and do not always reduce risk. Several studies have also found that moving 
from self-reported to known HCV status was not associated with any changes in PWID risk 
behavior (Miller, Mella, Moi, & Eskild, 2003; Ompad, Fuller, Vlahov, Thomas, & Strathdee, 
2002). Further, there is some suggestion that important differences may exist between the 
behavior of rural versus urban PWID with respect to self-reported HCV status and risk 
partner selection (Duncan et al., 2017).
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Ambivalent reactions on the part of PWID to their HCV infection status are perhaps not 
surprising. Given high HCV prevalence rates within the community, many PWID see the 
acquisition of HCV as an inevitable side-effect of injecting drugs (Norden et al., 2009; 
Nordén & Lidman, 2005; Rhodes & Treloar, 2008). Furthermore, considering that the 
disease itself remains asymptomatic for many years, it is not unreasonable that PWID would 
have different attitudes towards HCV than towards faster acting diseases such as HIV 
(Lansky et al., 2014; Rhodes & Treloar, 2008). However, this difference in attitude remains 
speculative without more evidence, leaving assumptions about the effectiveness of testing as 
intervention unchallenged. Moving forward, it remains important to examine how current 
risk network size may reflect past perceptions of one’s own HCV status.
In Puerto Rico, rural rather than urban communities seem to contribute disproportionately to 
overall HIV infection rates (Colón-López, Ortiz, Banerjee, Gertz, & Garcia, 2013; Norman, 
Dévieux, Rosenberg, & Malow, 2011; Pérez et al., 2010). Furthermore, over 20% of new 
HIV diagnoses in Puerto Rico listed injection drug use as their cause, compared to 8.3% in 
the continental United States (CDC, 2010). While similar surveillance data for HCV is not 
available from this area, related transmission scenarios indicate equivalent (or greater) risk 
for disparities in hepatitis (Abadie, Welch-Lazoritz, Gelpi-Acosta, Reyes, & Dombrowski, 
2016). Given the recent rise of HCV in rural mainland United States (Suryaprasad et al., 
2014), a recent HIV outbreak in the Midwest (Peters et al., 2016), and a continuing increase 
in rural drug use in general (Cicero, Ellis, Surratt, & Kurtz, 2014; Dombrowski, Crawford, 
Khan, & Tyler, 2016), the experiences of PWID in rural Puerto Rico provide timely insight 
into the trajectory of rural injection use in the contiguous United States.
The number of people a participant reports injecting with is an important aspect of an 
injection network. It is an indicator of potential exposure and transmission of HCV and HIV 
for both individuals and the larger network. Knowing the extent to which PWID are exposed 
to injection network risk is critical to understanding disease spread within this community 
(Dombrowski et al., 2013b, 2016b; Dombrowski, Curtis, Friedman, & Khan, 2013; 
Friedman et al., 1997; Khan, Dombrowski, Saad, McLean, & Friedman, 2013; Neaigus, 
Friedman, Kottiri, & Des Jarlais, 2001). We hypothesize that there will be a relationship 
between a participant’s HCV or HIV status and their injection network size, and that this 
relationship may not be the same for similar statuses—e.g., that HIV+ status will not 
necessarily reflect the same association with risk network degree that an HCV+ status will. 
Indeed, it is possible that, given documented expectations of HCV acquisition among PWID, 
self-reported HCV+ status may be associated with higher network degree (rather than the 
lower degree often seen among self-reported HIV+ PWID). While the studies cited above 
have established the importance of the relationship between HIV status and risk network 
size/degree, the same is not true for HCV status. Further, there is reason to believe that there 
are significant differences in PWID response to self-reported HCV status when compared 
with HIV (Abadie et al., 2016).
In what follows we use negative binomial regression to test whether self-reported HCV 
status predicts larger risk network sizes for active injectors in rural Puerto Rico. While the 
cross section nature of the data prevents us from examining how rural Puerto Rican PWID 
react to a change in self-reported status (as a result of a recent test, for example), these data 
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do allow us to investigate the association between self-reported status based on prior testing 
and current overall risk network size. Where prior research in the area has pointed to 
importance of self-reported HCV status on equipment sharing (Abadie et al., 2016), risk 
partner selection (Duncan et al., 2017) and overall risk network topology (Coronado-García 
et al., 2017); this analysis extends these investigations to the critical issue of overall risk 
network size.
Methods
Sample recruitment
Interviews with 315 participants were completed between April 2015 and June 2015 in the 
mountainous interior of Puerto Rico, 15-30 miles south of San Juan. Eligible participants 
were alert, 18 years of age or older, and had injected drugs within the last 30 days. Female 
injectors comprise 10% of the final analytical sample and the average age of participants 
was 42, ranging between 18 and 70. Interviews were conducted by a postdoctoral 
ethnographer alongside Puerto Rican staff working out of a storefront in one of the towns in 
the region while working in close association with the region’s only syringe exchange 
program. Transportation for participants from neighboring communities was facilitated by a 
regular pattern of van pick-up/drop-off. Continuing relationships were maintained with 
respondents in anticipation of planned additional rounds of data collection, including in situ 
ethnographic research. After completing the questionnaire, participants were compensated 
with $25. The study received IRB approval through the University of Nebraska-Lincoln 
(IRB# 20131113844FB) and the University of Puerto Rico (IRB# A8480115).
Respondent driven sampling was used to recruit participants, starting with two interviews 
(seeds) in each of the four focal towns. Seeds were recruited through collaboration with the 
only needle exchange in the area. Participants who completed the survey were given three 
referral coupons to pass out to other qualified individuals who had not previously 
participated in the project. For every referral that completed the survey, the referee could 
earn an additional $10. Respondent driven sampling differs from other methods in that the 
researcher never knows the number of people who may have been given a coupon and 
refused an interview. As such, traditional response rates are not applicable. Respondent 
driven sampling is often preferred for hidden and hard-to-reach populations (Johnston, 
Chen, Silva-Santisteban, & Raymond, 2013; Paquette, Bryant, & De Wit, 2011).
There is some risk of using a network based recruitment strategy to assess a network 
outcome. However, standard methods of RDS analysis (Gile & Handcock, 2010; Spiller, 
Cameron, & Heckathorn, 2012) were employed to control for network size in sample 
correction. Furthermore, a range of individual risk network size measures were collected 
from the sample and tested for the effects of “degree homophily” across a range of 
participant attributes on sample recruitment bias. These were shown to be nonsignificant for 
the variables used in this analysis, suggesting that the network size of the recruiter and the 
recruit did not influence recruitment patterns in the data considered here.
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Measures
The questionnaire was interviewer-administered and based on the CDC National HIV and 
Behavioral Surveillance (NHBS) of Injection Drug Users Round 3 Questionnaire version 13. 
The NHBS is designed to produce regular estimates of the number and behavior of PWID in 
23 urban areas in the United States; one of which is San Juan, Puerto Rico, an urban area 
north of this project’s target rural area. The instrument asked questions about injection 
behavior, prior HCV and HIV status and testing, and several other topics related to drug use 
and HIV/HCV risk.
In addition, the project provided rapid testing for both HIV and HCV using INSTI Rapid 
HIV antibody tests (Biolytical Laboratories) and OraQuick HCV Rapid antibody tests 
(OraSure Technologies). Participants were compensated an additional $5 for each test. The 
OraQuick HCV Rapid test is FDA approved and has demonstrated an accuracy rate greater 
than 98% (FDA, 2011). The test is not confirmatory evidence of a current HCV infection, as 
it cannot distinguish between antibodies which are present from a current or prior HCV 
infection. Participants who tested positive for HCV or HIV antibodies were offered referral 
and transportation to a primary care doctor for confirmatory testing and link-to-care.
The focal dependent variable for this article is the number of injection partners reported by 
participants in the study’s four focal towns. These towns are located in a contiguous region 
in the mountainous interior of Puerto Rico, 15-30 miles south of San Juan. Understanding 
that PWID in the area are often highly mobile (due to uneven supply, local enforcement 
trends, and financial reasons), participants were asked to estimate how many injection 
partners they currently have in each of these towns (i.e., “How many injecting partners do 
you have in town X”). Responses were summed to provide an overall number of injection 
partners in the region.
The primary focal independent variables are self-reported HCV and self-reported HIV status 
of the participant. These categories are defined by the participant’s report of having a prior 
positive HCV or HIV test, a prior negative HIV or HCV test, or having never been tested for 
either HIV or HCV. These results are classified as three categories for both HIV and HCV: a 
self-reported positive, a self-reported negative, or an unknown status. During the current 
survey, rapid antibody tests for HCV and HIV were administered to each participant in order 
to provide a current antibody status for HIV and HCV, providing comparisons between self-
reported and current status.
Other independent variables control for external factors, which may influence individual 
numbers of risk partners, including number of towns lived in and number of towns injected 
in within the region. These measure if the participant has ever lived or injected in any of the 
four communities with possible values ranging from zero to four. In addition, measures of 
the number of main sex partners and casual sex partners (as defined by NHBS) were 
collected and summed across each location. Frequency of injection is measured as 1-3 times 
per month (0), 1-6 times per week (1), 1-3 times per day (2), and 4 or more times per day 
(3). Years injecting is measured by subtracting the participant’s age when they first report 
injecting from their current age. Income is a dichotomous measure where (0) indicates 
having earned or received less than $5,000 in the past year and (1) is earnings above $5,000. 
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Education has three categories which are used as dummy variables: less than high school 
(1), completed high school (2), and any further education past high school (3). Marital status 
also has three categories: married or cohabiting (1); separated, divorced, or widowed (2); 
and single (3). Additionally, sex (female = 1), age (mean centered in models), and born in 
Puerto Rico (1) are used as controls in the models.
Data analysis
This article uses a two-pronged analytical strategy. Negative binomial regressions test the 
associations of controls and independent variables with the number of injection partners. 
This method is appropriate for dependent variables which are counts, over dispersed, and do 
not have an overabundance of zeros (Long, 1997). Models progress in a stepwise fashion as 
first controls and then possible explanatory variables are added in successive models. Results 
from the negative binomial models are presented and discussed in terms of percent change 
of the expected number of injection partners (i.e., incident rate ratios (Long & Freese, 
2006)). Multinomial logistic regression is then used to examine other possible associations 
between self-reported HCV and HIV statuses and the focal independent and control 
variables. These models are used for dependent variables which are categorical and nominal 
(Long, 1997). Results from the multinomial logistic regression models are presented and 
discussed in terms of percent change of the relative risk of reporting a self-reported HCV or 
HIV status (i.e., relative risk ratios (Long & Freese, 2006)). Due to limited missing data, the 
final sample is 297 out of the original 315 (listwise deletion).
Results
In the final sample 90% of the participants are male and are on average 42 years old (Table 
1). On average, participants reported 16 current injection partners across the focal locations, 
had been injecting for almost 20 years, and currently inject 1-3 times per day. A majority of 
the participants were born in Puerto Rico and reported receiving less than $5,000 in income 
and assistance in the previous year. The unbalanced sex distribution of the sample is unlikely 
to be an artifact of the RDS recruitment. Sample weighting from a range of RDS estimators 
(Gile & Handcock, 2010; Spiller et al., 2012; Wejnert, 2009) showed low levels of both 
degree and affiliation homophily by gender. The sampled distribution of gender is expected 
to be within 2-3 percentage points of the region’s PWID population proportion.
Almost 80% of the participants tested HCV+ according to the rapid antibody tests conducted 
at the end of the interview, but only 50% self-reported themselves as HCV positive before 
the test (Table 2). Approximately half those with an unknown HCV status had a positive 
HCV antibody test result. For those who reported a negative HCV result on their last test, 
65% tested positive through the antibody test during the interview. Six percent of the sample 
tested HIV+ in the rapid test and 4% knew they were HIV+ when they started. Two percent 
of those who reported a self-reported HIV− status tested HIV+, and 6% of those who 
reported an unknown status tested HIV+. Few participants with a self-reported positive 
status received a negative antibody test (0% of HIV+ participants and 3% of HCV+ 
participants).
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Table 3 shows a series of negative binomial regression models that explore the association 
between several factors and the expected number of injection partners. Models 1-3 show 
simplified models where the association between self-reported HCV and HIV status are 
examined individually and then in tandem with the expected number of injection partners. In 
Model 1 the expected number of injection partners is higher for those with a self-reported 
HCV unknown status (+88%, p < 0.01) and for those with a self-reported HCV+ status 
(+146%, p < 0.001) compared to those with a self-reported HCV− status. Model 2 shows 
that there is no significant association between self-reported HIV status and the expected 
number of injection partners. In Model 3, which tests self-reported HCV and HIV status we 
see a similar pattern from Model 1. Self-reported Unknown HCV and self-reported HCV+ 
status are associated with greater expected counts of injection partners (+106%, p < 0.01; 
+ 156%, p < 0.001) compared to those with a self-reported HCV− status. Unlike prior 
models, Model 3 shows a negative association between self-reported HIV+ (−54%, p < 0.05) 
and the expected count of injection partners when compared to those with a self-reported 
HIV− status.
Models 4 and 5 then test the association between self-reported HCV and HIV statuses and 
the number of injection partners independently with controls. Here, reporting a self-reported 
unknown HCV status is associated with a higher expected number of injection partners 
(+82%, p < 0.01) than those reporting a self-reported HCV− status. Similarly, a self-reported 
HCV+ status is associated with a much higher expected number of injection partners 
(+117%, p < 0.001) than a HCV− status. There are no statistically significant associations 
between self-reported HIV status and the expected number of injection partners found.
Model 6 of Table 3 includes all controls and predictors and shows that the expected number 
of injection partners is significantly associated with being single compared to being married 
or cohabiting (+46% p < 0.05). The expected number of injection partners also increases for 
every year a participant has been injecting (+2%, p < 0.05) and for every additional focal 
town ever injected in (+84%, p < 0.001). The expected number is higher for HCV unknown 
(+102%, p < 0.001) and HCV+ self-reported statuses (+124%, p < 0.001) than for a self-
reported HCV− status. The association between a self-reported HIV+ status and the 
expected number of injection partners is only marginally significant in a full model with 
controls compared to a self-reported unknown HIV status. The final model thus shows that 
even under considerable controls, reported unknown and positive HCV statuses are 
significantly associated with approximately double the expected injection network size than 
those with a self-reported negative HCV status.
Although the differences in injection network size are clear, it is possible that there is a 
common factor associated with these differences that then influences a participant’s self-
reported HCV or HIV status. A multinomial logistic regression model tests the differences 
between reporting self-reported HCV and HIV statuses (Table 4). For HCV, the only 
significant association is that the relative risk of a participant reporting a self-reported HCV 
unknown status rather than a HCV− status is 8.498 times greater when the participant 
reports an HIV unknown status rather than a HIV− status. For self-reported HIV status, a 
one year increase in the participant’s age is associated with an 8.4% (p < 0.05) lower relative 
risk of that participant reporting a self-reported HIV unknown status than a HIV− status. 
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Participants who are single compared to those who are currently together have a greater 
relative risk (+231%, p < 0.05) of self-reporting an unknown HIV status compared to a HIV
− status. Those who self-reported an unknown HCV status have a greater relative risk 
(+740%, p < 0.001) of reporting an unknown HIV status as well. Finally, participants who 
inject more frequently are associated with a lower relative risk (−54%, p < 0.05) of reporting 
a self-reported HIV+ status than a HIV− status. The majority of the controls and possible 
other explanations for the relationships in Table 3 remain non-significant for both models.
Discussion
There are clear associations between the number of injection partners and self-reported HCV 
status among rural PWID in Puerto Rico. On average, those who think that they are HCV 
negative have half the expected number of current injection partners than those who are 
either HCV positive or do not know their HCV status. These associations are different for 
HIV, where there are no significant associations. Multinomial logistic regressions reveal few 
differences associated with self-reported HCV status. Therefore, it is likely that the observed 
differences in injection network sizes among these participants are associated with how they 
view HCV and HIV.
In other settings, HCV is seen as omnipresent and an inevitable consequence of injecting 
drugs by users themselves (Norden et al., 2009; Nordén & Lidman, 2005; Rhodes & Treloar, 
2008), and PWID in rural Puerto Rico are unlikely to be an exception. In this context, it is 
perhaps unsurprising that those who do not know their status have similar behavior to those 
who self-report a HCV+ status. Many of those who do not know their status may assume 
they are infected, and similarly, may assume that their potential risk partners are the same. A 
lack of perceived risk may determine many interactions, especially when one considers that 
HCV is perceived as a far less threatening infection than HIV (Rhodes & Treloar, 2008). 
Under these conditions, a negative HCV status may motivate greater risk avoidance than a 
positive or unknown one, and may prompt some self-protective action.
Though it’s limited, evidence for this has been discussed for other locations (Norden et al., 
2009; Vidal-Trécan et al., 2000). In their qualitative synthesis of the literature on HCV, 
Rhodes and Treloar (2008) found a trend toward the individualization of responsibility as a 
major theme raised by injectors when discussing their attitudes toward risk of HCV 
infection. Such considerations were paramount in balancing health risk and drug intake to 
avoid withdrawal while maintaining social ties critical to future drug access (Samuel R. 
Friedman, Sandoval, Mateu-Gelabert, Meylakhs, & Jarlais, 2011). The situation is clearly 
complex, but a simple solution for PWID who perceive their HCV status as negative may be 
reducing the number of people they inject with. As smaller personal injection networks 
entail less exposure risk.
Among injectors in rural Puerto Rican, self-reported HIV status was not associated with the 
expected number of injection partners in models with controls. This stands against what 
would be anticipated given evidence from other settings, that HIV positive PWID would be 
more likely to disclose their status to injection partners (Nordén & Lidman, 2005), which 
would in turn potentially reduce the number of possible injection partners. The absence of 
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similar findings here may be due to the small number of people in the sample who reported 
themselves to be HIV positive (4%), or it may reflect an artificial situation where HIV 
positive PWIDs are, at times unwillingly, sent to the mainland United States for treatment 
programs by local municipalities, and are thus removed from the environment of this study 
(Perez Torruella, 2010).
In addition to self-reported HCV status, the expected number of injection partners was also 
associated with the number of towns in the region a participant injected in, single 
participants compared to married or cohabiting participants, and those who have been 
injecting for a longer period of time. These associations collectively indicate that 
participants with the largest injection networks would be those who are single, have injection 
partners in multiple towns, have been injecting for many years, and who have a self-reported 
HCV positive or unknown status.
Although many of these associations are quite substantial in size, they offer complex 
guidance for the development of policy. Marital status or the ability of individuals to move 
freely in their own country are not attributes which are easily modified through policy, nor 
should they be. Furthermore, in places where most or even all PWID expect to already be (or 
become) HCV positive and social pressure to truthfully disclose HCV status is low, 
“testingas-intervention” strategies like those found to reduce risk among HIV positive PWID 
may not be as effective in rural Puerto Rico.
Considering HCV to be a routine consequence of injecting among rural PWID may seem 
unreasonable in many places given the seriousness of HCV infection, but in Puerto Rico, 
where state provided insurance does not cover HCV care for HIV negative patients, these 
expectations may reflect larger social disconcern. Here, we speculate that greater 
expectations of engaging risk partners who are HCV negative could potentially change these 
results, but this may require a larger change in the social value placed in HCV prevention. 
The extent to which a lack of services contributes to this pattern of behavior and risk 
assessments goes beyond the data available to us at this stage of the research, but we note 
that syringe exchange access in the region is limited to a single mobile operation covering a 
large rural area while attempting to serve a highly mobile population (López et al., 2015).
Limitations
Although we have outlined scenarios where injection network size is associated with health 
statuses, injection frequency is not associated with either the size of injection networks or 
the participant’s self-reported HCV or HIV status. A smaller injection network may reduce 
the reach of a disease spreading within the larger network, but the frequency of injection sets 
the pace for a disease to jump between two individuals (Mackesy-Amiti et al., 2011). 
Limiting the size of an individual’s personal injection risk network may, therefore, not 
influence the risk of transmission for a given dyad when injection frequency remains the 
same.
These findings are also limited by the cross-sectional nature of the study. The lack of time 
depth is, to some extent, addressed by looking at how self-reported disease status (which is 
based on past HCV/HIV testing) is associated with differences in current behavior, thereby 
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associating prior attitudes with current practice. However, there is no substitute for a 
longitudinal study. This limitation is compounded by evidence that HCV diagnoses in 
particular can be highly variable in terms of quality, information, and empathy (Treloar, 
Newland, Harris, Deacon, & Maher, 2010).
Another limitation is that the number of HIV+ participants is low and likely causing cell size 
problems in Table 4. Our understanding, informed by research elsewhere in the United 
States, is that low HIV prevalence levels are not simply a reflection of low HIV incidence in 
Puerto Rico. As noted above, HIV+ PWID in rural Puerto Rico have reportedly been sent to 
the mainland United States for treatment by local municipalities and may therefore be 
uniquely underrepresented in this data (Perez Torruella, 2010).
Conclusion
Despite these limitations, the results presented here provide a clear view of how the number 
of injection partners varies in association with knowledge of HCV status. In an environment 
with high levels of HCV, it is the minority group, the ones who have not acquired HCV and 
are aware of that status, that have the lowest number of injection partners. Those who are 
HCV positive or unaware of their status have twice as many injection partners. Several 
alternative explanations for larger injection networks such as age, years of injecting, the 
number of towns a person has lived or injected in, and their number of sexual partners have 
been included and the focal relationship persists. We view this as evidence that the 
knowledge of a previous HCV− test (which defines an unknown from a negative status) is 
associated with a decision to reduce injection network sizes, and a self-reported HCV+ or 
unknown status does not.
If our desire is to reduce the spread of HCV (of which injection network size is a 
component) then we suggest that practitioners attempt to confirm HCV− status when 
possible and helping users develop safe injection practice before HCV is acquired. Although 
this may appear similar to those involving outreach HIV testing, the latter is frequently 
focused on identifying individuals with a positive status and helping them to minimize the 
risk of HIV spread while managing the health consequences of their new diagnoses 
(MacArthur et al., 2014).
The time frame during which a HCV− intervention can be staged is limited however, 
especially among active injectors in HCV saturated environments such as that found in rural 
PR. Similarly, a focus on locating PWID who have negative status later in their injection 
careers (either due to clears, long-term behavior, or recent developments in HCV cures) 
would require very active surveillance. The result, however, could help establish different 
expectations toward the likelihood of future HCV infection. This in turn could potentially 
lower the overall level of network risk through reducing the average number of network 
injection partners throughout the network. Such a change can have implications for disease 
transmission across a range of pathogens. Furthermore, as novel HCV treatment protocols 
increase the number of mid-career HCV negatives, efforts to prevent reinfection grow more 
important.
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Reaching injectors early and consistently can be challenging. Research has found that 78% 
of injection partnerships involve behaviors with a high risk of HCV transmission (Brewer et 
al., 2006) and that newer injectors quickly acquire HCV (E. R. Miller, Hellard, Bowden, 
Bharadwaj, & Aitken, 2009). This provides a short window of time to deliver a HCV test. 
Here, work with existing prevention programs such as syringe exchange programs (SEPs) is 
likely to be critical to prevention success. SEPs are likely to recognize new injectors, but 
seldom have available the means for field-testing for HCV due to financial limits or lack of 
facilities. The results discussed here, however, indicate that for rural Puerto Rico, and 
perhaps other rural locations as well, attempting to confirm HCV− statues alongside harm 
reduction interventions already aimed at reaching rural populations may be effective for 
HCV prevention.
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Table 1
Descriptive statistics (n = 297).
Variables Mean/% Std. D. Min Max
Number of injection partners (current) 15.72 22.20 0 159
Female 10% 0.30 0 1
Age 41.89 10.17 18 70
Income: greater than or equal to $5,000 20% 0.40 0 1
Born in Puerto Rico 93% 0.26 0 1
Education
 Less than high school 47% 0.50 0 1
 High school 35% 0.48 0 1
 More than high school 18% 0.39 0 1
Marital status
 Together (married/cohabiting) 22% 0.41 0 1
 Previously married (divorced/widowed/separated) 31% 0.46 0 1
 single 47% 0.50 0 1
Employed FT/PT/retired/student(ref = unemployed) 11% 0.31 0 1
Number of years injecting 19.97 10.71 0 52
Frequency of injection 2.19 0.83 0 3
Number of focal towns lived in (ever) 1.20 0.59 0 4
Number of focal towns injected in (ever) 1.63 0.86 0 4
Number of main sex partners (current) 1.87 3.70 0 32
Number of casual sex partners (current) 2.69 5.23 0 41
Self-reported HIV status
 HIV unknown 10% 0.30 0 1
 Self-Reported Negative Status 86% 0.35 0 1
 Self-reported positive status 4% 0.20 0 1
HIV+ antibody post survey test 6% 0.25 0 1
Self-reported HCV status
 HCV unknown 23% 0.42 0 1
 Self-reported negative status 27% 0.45 0 1
 Self-reported positive status 49% 0.50 0 1
HCV+ antibody post survey test 78% 0.41 0 1
N 297
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Table 2
Percent distribution of antibody test results by participant’s self-reported HCV or HIV status prior to the 
antibody test (n = 297).
Negative Positive Total
Self-reported HCV status HCV antibody test result
Unknown Status 46% (32) 54% (37) 23% (69)
Self-reported negative 34% (28) 66% (54) 27% (82)
Self-reported positive 3% (2) 97% (148) 50% (152)
Total 21% (64) 79% (239)
Self-reported HIV status HIV antibody test result
Unknown status 93% (41) 7% (3) 14% (44)
Self-reported negative   98% (254) 2% (4) 82% (258)
Self-reported positive 7% (1) 92% (12) 4% (13)
Total   94% (296)   6% (19)
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Table 4
Multinomial logistic regression models predicting perceived HCV and HIV status (n = 297).
Variables
HVC self-reported status (ref: Negative) HIV self-reported status (ref: Negative)
Unknown Positive Unknown Positive
Female 0.876
[0.24, 3.15]
1.104
[0.43, 2.85]
0.386
[0.07, 2.18]
2.254
[0.27, 18.9]
Age (mean centered) 0.973
[0.92, 1.03]
0.994
[0.96, 1.03] 0.916
*
[0.85, 0.99]
1.063
[0.96, 1.18]
Together: Married or Cohabiting (reference) Reference Reference Reference Reference
Previously Married 0.577
[0.20, 1.67]
0.789
[0.34, 1.81] 3.111
+
[0.86, 11.3]
0.349
[0.05, 2.35]
Single 0.794
[0.30, 2.07]
1.141
[0.52, 2.48] 3.308
*
[1.02, 10.7]
0.552
[0.09, 3.25]
# of Years Injecting 1.024
[0.97, 1.08]
1.027
[0.99, 1.07]
1.041
[0.98, 1.12]
1.047
[0.96, 1.14]
# of Focal Towns Lived In (ever) 1.044
[0.53, 2.07]
0.919
[0.54, 1.55]
1.180
[0.57, 2.45]
0.805
[0.22, 2.96]
# of Focal Towns Injected In (ever) 1.028
[0.62, 1.70] 1.394
+
[0.99, 2.07]
0.781
[0.46, 1.33]
0.752
[0.29, 1.97]
Frequency of Injection 1.280
[0.81, 2.03]
1.067
[0.76, 1.50]
1.047
[0.64, 1.71] 0.460
*
[0.21, 0.99]
# of Main Sex Partners (current) 0.981
[0.84, 1.15]
1.064
[0.95, 1.20]
0.895
[0.64, 1.71]
0.746
[0.43, 1.29]
# of Casual Sex Partners (current) 1.053
[0.95, 1.16]
0.990
[0.91, 1.08]
1.056
[0.97, 1.15]
1.100
[0.90, 1.34]
HIV: Unknown Status 8.498***
[2.82, 25.6]
1.578
[0.51, 4.90]
HIV: Self-Reported Positive Status 0.000
[0.00, 0.00]
1.916
[0.46, 7.96]
HIV: Self-Reported Negative Status (reference) Reference Reference
HCV: Unknown Status 8.397***
[2.77, 25.5]
0.000
[0.00, 0.00]
HCV: Self-Reported Positive Status 1.596
[0.51, 5.01]
3.152
[0.57, 17.6]
HCV: Self-Reported Negative Status (reference) Reference Reference
Intercept 0.085+ 0.413 0.075 2.824
N 297 297
Pseudo R2 0.11 0.25
Coefficients are presented as relative risk ratios and 95% confidence intervals are presented below:
+p < 0.10,
*p < 0.05,
**p < 0.01,
***p < 0.001. Not shown are non-significant coefficients for being born in Puerto Rico, income, education, and current employment status.
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